Can a Single Dose of Lysergide Offer Lasting Relief for Depression?
Recent Phase 3 clinical data from the EMERGE trial highlights DT120—a proprietary, fast-dissolving oral formulation of lysergide (LSD)—which demonstrated rapid, clinically meaningful improvements in patients with major depressive disorder (MDD) after just a single monitored dose. With the FDA granting it Breakthrough Therapy designation, explore how this novel approach works, the trial data behind the headlines, and its potential impact on modern psychiatry.
Congratulations to our CEO and Principal Investigator, John Sonnenberg, PhD, for being featured in the Psychiatry Advisory's article! Uptown Research Institute continues to follow its mission of bringing science to practice. A link to the full article is provided below:
https://www.psychiatryadvisor.com/cch/psychedelics-major-depressive-disorder-therapy-lysergide-lsd-dt120-odt/